Corvus Pharmaceuticals Company Insiders
| CRVS Stock | USD 8.93 0.02 0.22% |
Corvus Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Corvus Pharmaceuticals suggests that vertually all insiders are extremely bullish. Corvus Pharmaceuticals employs about 28 people. The company is managed by 8 executives with a total tenure of roughly 28 years, averaging almost 3.0 years of service per executive, having 3.5 employees per reported executive.
| William Jones President Vice President of Pharmaceutical Development |
| Erik Verner President Vice President of Chemistry Research |
Corvus Pharmaceuticals' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-05-06 | William Benton Jones | Acquired 20000 @ 1.73 | View |
Monitoring Corvus Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Corvus |
Corvus Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Corvus Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Corvus will maintain a workforce of slightly above 40 employees by December 2024.Corvus Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2383) % which means that it has lost $0.2383 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4491) %, meaning that it created substantial loss on money invested by shareholders. Corvus Pharmaceuticals' management efficiency ratios could be used to measure how well Corvus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.62 in 2024. Return On Capital Employed is likely to drop to -0.63 in 2024. At this time, Corvus Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 72.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 687.3 K in 2024.Common Stock Shares Outstanding is likely to drop to about 30.7 M in 2024. Net Loss is likely to drop to about (39 M) in 2024
Corvus Pharmaceuticals Workforce Comparison
Corvus Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 714. Corvus Pharmaceuticals holds roughly 28.0 in number of employees claiming about 4% of equities under Health Care industry.
Corvus Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Corvus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Corvus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Corvus Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2021-09-01 | 3.6667 | 11 | 3 | 755,000 | 5,219,288 |
| 2020-09-01 | 0.5 | 1 | 2 | 30,000 | 1,538,062 |
| 2020-06-01 | 7.0 | 7 | 1 | 105,000 | 0.00 |
| 2019-09-01 | 2.0 | 6 | 3 | 411,298 | 1,492,956 |
| 2018-12-01 | 2.5 | 10 | 4 | 611,202 | 120,000 |
| 2018-03-01 | 15.0 | 15 | 1 | 3,729,410 | 0.00 |
| 2016-03-01 | 2.3158 | 44 | 19 | 20,217,081 | 16,205,545 |
Corvus Pharmaceuticals Notable Stakeholders
A Corvus Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Corvus Pharmaceuticals often face trade-offs trying to please all of them. Corvus Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Corvus Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| William Jones | Vice President of Pharmaceutical Development | Profile | |
| Erik Verner | Vice President of Chemistry Research | Profile | |
| Leiv Lea | Chief Officer | Profile | |
| James MD | Senior Research | Profile | |
| Alan Esq | Sec | Profile | |
| MD FACP | CoFounder Director | Profile | |
| Jeffrey Arcara | Chief Officer | Profile | |
| Richard MD | President, CoFounder | Profile |
About Corvus Pharmaceuticals Management Performance
The success or failure of an entity such as Corvus Pharmaceuticals often depends on how effective the management is. Corvus Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Corvus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Corvus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (0.70) | (0.66) |
Please note, the imprecision that can be found in Corvus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corvus Pharmaceuticals. Check Corvus Pharmaceuticals' Beneish M Score to see the likelihood of Corvus Pharmaceuticals' management manipulating its earnings.
Corvus Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Corvus Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Corvus Pharmaceuticals within its industry.Corvus Pharmaceuticals Manpower Efficiency
Return on Corvus Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 965.3K | |
| Net Loss Per Executive | 3.4M | |
| Working Capital Per Employee | 753.1K | |
| Working Capital Per Executive | 2.6M |
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.